Tumor-associated macrophages—additional effectors at anti-PD-1/PD-L1 therapy?
نویسندگان
چکیده
منابع مشابه
Anti-tumor effects of anti-PD-L1 therapy in an orthotopic bladder tumor model
Antibodies that block PD-1/PD-L1 interactions have shown efficacy against both lung and skin cancers in early-stage clinical trials, and may also be effective in other tumor types, particularly bladder tumors. PD-L1 expression has been previously reported to correlate with high-grade tumors, a high recurrence rate, and reduced survival rate in patients with bladder cancer. These findings and th...
متن کاملNoninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies.
Antibodies that block the interaction between programmed death ligand 1 (PD-L1) and PD-1 have shown impressive antitumor activity. Patients with tumors expressing PD-L1 are most likely to respond to this treatment. The aim of our study was to develop a noninvasive imaging technique to determine tumor PD-L1 expression in vivo. This could allow selection of patients that are most likely to benefi...
متن کاملImproved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models
Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models Jessica Spahn, Jing Peng, Edward Lorenzana, David Kan, Thomas Hunsaker, Ehud Segal, Mario Mautino, Erik Brincks, Andrea Pirzkall, Sean Kelley, Sami Mahrus, Liling Liu, Stephanie Dale, Cristine Quiason, Elizabeth Jones, Yichin Liu,...
متن کاملTargeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.
Genetic alterations and epigenetic dysregulation in cancer cells create a vast array of neoepitopes potentially recognizable by the immune system. Immune checkpoint blockade has the capacity to enhance and sustain endogenous immunity against non-mutated tumor-associated antigens as well as uniquely mutant antigens, establishing durable tumor control. Recent evidence from preclinical models high...
متن کاملAnti-PD-1/PD-L1 therapy of human cancer: past, present, and future.
Major progress has been made toward our understanding of the programmed death-1/programmed death ligand-1 (PD-1/PD-L1) pathway (referred to as the PD pathway). mAbs are already being used to block the PD pathway to treat human cancers (anti-PD therapy), especially advanced solid tumors. This therapy is based on principles that were discovered through basic research more than a decade ago, but t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Disease
سال: 2017
ISSN: 2072-1439,2077-6624
DOI: 10.21037/jtd.2017.10.15